Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.1
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 12,435 $ 9,170
General and administrative 4,521 3,829
Total operating expenses 16,956 12,999
Loss from operations (16,956) (12,999)
Other income:    
Interest income 1,102 53
Net loss (15,854) (12,946)
Other comprehensive income:    
Net unrealized loss on available-for-sale investments, net of tax 47 (152)
Net comprehensive loss $ (15,807) $ (13,098)
Net loss per share of voting and non-voting common stock, basic $ (0.45) $ (0.45)
Net loss per share of voting and non-voting common stock, diluted $ (0.45) $ (0.45)